Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611033 · ClinicalTrials.gov registry record · Phase 1
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT06611033 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 65 participants.
The verdict
NCT06611033, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL PREVNAR 20™
- BIOLOGICAL V118C
- BIOLOGICAL V118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06611033
The ClinicalTrials.gov registry entry for NCT06611033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT06611033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06611033 about?
NCT06611033 is a clinical study titled "A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)". The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
What is the current status of trial NCT06611033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2024-09-25. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06611033?
The interventions under investigation include: Saline (BIOLOGICAL), PREVNAR 20™ (BIOLOGICAL), V118C (BIOLOGICAL), V118 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06611033?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.